Xembify Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis rates of primary immunodeficiency diseases, wider availability of plasma-derived therapies, growing awareness among healthcare professionals, expansion of specialty immunology clinics, improved cold chain distribution capabilities.

The growth in the forecast period can be attributed to increasing prevalence of chronic immune disorders, rising demand for self-administered therapies, expansion of homecare infusion services, growing investments in plasma collection infrastructure, ongoing advancements in immunoglobulin formulation science. Major trends in the forecast period include increasing adoption of subcutaneous immunoglobulin therapies, rising preference for home-based immunoglobulin administration, growing focus on patient-centric treatment protocols, expansion of long-term immunodeficiency management solutions, improved stability and formulation advancements.

The rising prevalence of primary immunodeficiency diseases (PI) is expected to drive the growth of the xembify market in the coming years. Primary immunodeficiency diseases are conditions in which the immune system is deficient or absent, reducing the body's ability to fight infections and increasing vulnerability to illnesses. The growing prevalence of PI is attributed to advances in diagnostic techniques, greater awareness, improved genetic testing, and the identification of previously undiagnosed cases. Xembify plays a key role in managing PI by providing immunoglobulin therapy that enhances the immune system and improves patient outcomes. For example, according to a report published in August 2023 by Thermo Fisher, a US-based life sciences and clinical research company, an estimated 6 million people globally have a primary immunodeficiency (PID), with around 5,000 individuals affected in the UK. Consequently, the rising prevalence of PI is expected to drive the growth of the xembify market.

The increase in healthcare spending is also expected to support the expansion of the xembify market. Healthcare spending refers to the total resources allocated by governments, private entities, and individuals toward medical services, including research, infrastructure, treatments, preventive measures, and innovative therapies. Growth in healthcare spending is driven by factors such as the increasing prevalence of chronic and rare diseases, advancements in medical technology, rising health awareness, aging populations, and a focus on improving healthcare infrastructure. Higher healthcare investment supports awareness campaigns and screening programs for primary immunodeficiency diseases. Early diagnosis enables earlier intervention with treatments like Xembify, increasing adoption. For instance, according to the U.S. Centers for Medicare & Medicaid Services, in December 2024 U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare spending is contributing to the growth of the xembify market.

A key trend in the xembify market is the expansion of indications, such as the 20% subcutaneous immunoglobulin (SCIg) product, which provides more flexible dosing options for patients with primary immunodeficiency and other immune-related conditions. The 20% SCIg product is a concentrated form of immunoglobulin G (IgG) administered subcutaneously to strengthen the immune system. For example, in July 2024, Grifols, S.A., a Spain-based pharmaceutical and chemical company, received U.S. Food and Drug Administration (FDA) approval to expand the label of XEMBIFY to include treatment-naïve patients with primary humoral immunodeficiencies (PI). This made XEMBIFY the first 20% SCIg therapy that can be administered without prior intravenous treatment, offering patients greater convenience and flexibility. This milestone highlights Grifols’ commitment to improving patient outcomes through innovative and patient-friendly immunoglobulin therapies.

Major companies operating in the xembify market are Grifols S.A.

North America was the largest region in the xembify market in 2025. The regions covered in the xembify market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xembify market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the xembify market by increasing costs associated with imported plasma-derived raw materials, sterile packaging components, cold-chain logistics equipment, and specialized manufacturing consumables. North America and Europe are most affected due to reliance on cross-border plasma sourcing and biologics manufacturing inputs, while Asia-Pacific faces rising import costs for finished immunoglobulin products. These tariffs are contributing to higher production and distribution expenses and may influence treatment affordability. However, they are also encouraging regional plasma collection expansion, localized manufacturing investments, and supply chain diversification to improve long-term market resilience.

The xembify market research report is one of a series of new reports that provides xembify market statistics, including xembify industry global market size, regional shares, competitors with a xembify market share, detailed xembify market segments, market trends and opportunities, and any further data you may need to thrive in the xembify industry. This xembify market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xembify is a brand of immune globulin subcutaneous (human), used to treat primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). This immunoglobulin therapy helps strengthen the immune system by supplying antibodies that the body may not produce sufficiently.

The primary indications for Xembify include primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, immune thrombocytopenia (ITP), and multifocal motor neuropathy (MMM). Primary immunodeficiency is a group of genetic disorders that impair the immune system, increasing susceptibility to infections and immune-related complications. Xembify is distributed through direct sales, pharmacies, and online retailers, and is used by various end users, including hospitals, clinics, and home care settings.

The xembify market consists of sales of pre-filled syringes, vials, infusion pumps, administration sets, and other required tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.